Michelle Wallander

Dr. Michelle Wallander

orcid

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 September 2024 in Transplantation and Cellular Therapy
Verified
Journal Article
Open access
BHBei Hu
Bei Hu
RVRakhee Vaidya
Rakhee Vaidya
FAFerdous Ahmed
Ferdous Ahmed
HEHamid Ehsan
Hamid Ehsan
TMTamara K Moyo
Tamara K Moyo
NGNilanjan Ghosh
Nilanjan Ghosh
The implementation of CAR T therapy in the real-world setting is hindered by logistical and financial barriers, impacting timely access to this life-saving treatment. Clinical trials have reported the time from leukapheresis to CAR T cell infusion (vein-to-vein time) but not the time from CAR T referral to infusion (decision-to-vein time). Herein, we report the barriers to CAR T therapy in a real-world setting. We evaluated the factors influencing the decision-to-vein time and explored the association with clinical outcomes in patients with relapsed or refractory DLBCL who received CAR T therapy. We conducted a retrospective study of adult patients with R/R DLBCL who underwent consultation for CAR T cell therapy at Levine Cancer Institute and Wake Forest Comprehensive Cancer Center and collected information regarding demographic data, referral type, insurance type, CAR T product and survival outcomes. The effects of variables on decision-to-vein time were analyzed by Fisher's exact test for categorial variables and Wilcoxon rank-sum test for continuous variables. Survival analyses were performed using Kaplan-Meier and Cox Proportional Hazard models. The study included 142 patients who were referred for CAR T of which 99 patients received CAR T. Median decision-to-vein time was 62 days compared to median vein-to-vein time of 32 days. Patients with private insurance took longer to obtain financial clearance compared to patients with government insurance (median 25 vs. 9 days, p < .001). Of those with private insurance (n=63), 35% needed a single case agreement (SCA) which led to significant delay in receiving financial clearance (median 50.5 vs.19 days, p < .001) and increased decision-to-vein time (median 75 vs. 55 days, p < .001) compared to those who did not need SCA. Decision-to-vein time was significantly different among various products, clinical trial being the shortest (median 47 days, n = 9) and non-conforming products being the longest (median 94.5 days, n = 6) (p< .001). Axi-cel had the shortest median decision-to-vein time at 61 days compared to 81 days with tisa-cel and 85 days with liso-cel. Although delays in receiving CAR T therapy did not impact survival, the median overall survival for patients who were referred for CAR T therapy but did not receive it, was significantly lower than those who received CAR T cell therapy (9.0 vs. 21.0 months, p < .001). Decision-to-vein time is a major cause of delay in receiving CAR T therapy. SCAs lead to significant increase in 'decision-to-vein' time leading to delays in CAR T therapy in a real-world setting. Patients who were referred for CAR T but are not able to receive it, have inferior survival compared to CAR T recipients. Our findings underscore the significance of addressing administrative hurdles, such as SCAs and insurance approvals, for timely access to CAR T therapy for patients with DLBCL.

21 November 2024 in BMJ Quality & Safety
Verified
Journal Article
Closed access
PDF file
IOIfeyinwa Osunkwo
Ifeyinwa Osunkwo
JCJennifer S Cornette
Jennifer S Cornette
LNLaura Noonan
Laura Noonan
CCCheryl Courtlandt
Cheryl Courtlandt
SMSarah Mabus
Sarah Mabus
RLRaymona H Lawrence
Raymona H Lawrence
Background Individuals with sickle cell disease (SCD) experience poor clinical outcomes while transitioning from paediatric to adult care. Standards for SCD transition are needed. We established a Quality Improvement (QI) Collaborative that aimed to improve the quality of care for all young adults with SCD by establishing a standardised SCD transition process. This study evaluates the implementation of the Six Core Elements (6CE) of Health Care Transition, which was a fundamental component of the cluster-randomised Sickle Cell Trevor Thompson Transition Project (ST3P-UP) study. Methods A central QI team trained 14 ST3P-UP study sites on QI methodologies, 6CE and Got Transition’s process measurement tool (PMT). Site-level QI teams included a transition coordinator, clinic physicians/staff, patients/parents with SCD and community representatives. Sites completed the PMT every 6 months for 54 months and monthly audits of 10 randomly-selected charts to verify readiness/self-care assessments and emergency care plans. Results Of a possible 100, the aggregate mean (±SD) PMT score for paediatric clinics was 23.9 (±13.8) at baseline, 95.9 (±6.0) at 24 months and 98.9 (±2.1) at 54 months. The aggregate mean PMT score for adult clinics was 15.0 (±13.5) at baseline, 88.4 (±11.8) at 24 months and 95.8 (±6.8) at 54 months. The overall QI Collaborative PMT score improved by 402%. At baseline, readiness/self-care assessments were current for 38% of paediatric and 20% of adult patients; emergency care plans were current for 20% of paediatric and 3% of adult patients. Paediatric clinics had one median readiness assessment shift (76%) and four median emergency care plan shifts (65%, 77%, 79%, 84%). Adult clinics experienced three median self-care assessment shifts (58%, 63%, 70%) and two median emergency care plan shifts (57%, 70%). Conclusions The ST3P-UP QI Collaborative successfully embedded the 6CE of Health Care Transition into routine care and increased administration of assessments and emergency care plans for transition-aged patients with SCD.

1 July 2011 in Applied Immunohistochemistry & Molecular Morphology
Verified
Journal Article
Closed access
Ting LiuTing Liu
Ting Liu
CWCarlynn Willmore-Payne
Carlynn Willmore-Payne
MWMichelle Wallander
Michelle Wallander
LLLester J Layfield
Lester J Layfield
Endometrial adenocarcinomas are associated with a variety of molecular abnormalities including microsatellite instability, Kirsten rat sarcoma viral oncogene homolog mutations, and phosphatase and tensin homolog inactivation. Recently, mutations in fibroblast growth factor receptor 2 (FGFR2) have been described but their frequency and clinicopathologic characteristics are incompletely known. To determine the frequency of mutations in FGFR2 exons 7 and 12, 43 adenocarcinomas of the endometrium were studied by high-resolution melting analysis utilizing unlabeled probes and sequencing. Three of 43 (7%) endometrial carcinomas harbored FGFR2 exon 7 mutations. All 3 mutations were S252W and occurred in endometrioid (type I) adenocarcinomas. Direct sequencing indicated that 2 of the S252W mutations were heterozygous, whereas 1 was presumably homozygous. No FGFR2 mutations were detected in exon 12. FGFR2 mutations occur in approximately 7% of adenocarcinomas of the endometrium. Only carcinomas of an endometrioid morphology contain FGFR2 mutations, and in our series all were S252W. FGFR2 exons 7 and 12 unlabeled DNA probes allow for easy screening of endometrial carcinoma for the 2 most common FGFR2 mutations (S252W and N550K). Identification of these mutations may have important implications in directed molecular therapy.

18 February 2023 in Current Oncology
Verified
Journal Article
Open access
PDF file
MSMalcolm Squires
Malcolm Squires
EDErin E. Donahue
Erin E. Donahue
MWMichelle Wallander
Michelle Wallander
STSally J. Trufan
Sally J. Trufan
RSReilly E. Shea
Reilly E. Shea
JSJonathan C. Salo
Jonathan C. Salo
The National Surgical Quality Improvement Project (NSQIP) dataset was used to identify perioperative variables associated with the length of stay (LOS) and early discharge among cancer patients undergoing colectomy. Patients who underwent non-emergent right colectomy for colon cancer from 2012 to 2019 were identified from the NSQIP and colectomy-targeted databases. Postoperative LOS was analyzed based on postoperative day (POD) of discharge, with patients grouped into Early Discharge (POD 0–2), Standard Discharge (POD 3–5), or Late Discharge (POD ≥ 6) cohorts. Multivariable ordinal logistic regression was performed to identify risk factors associated with early discharge. The NSQIP query yielded 26,072 patients: 3684 (14%) in the Early Discharge, 13,414 (52%) in the Standard Discharge, and 8974 (34%) in the Late Discharge cohorts. The median LOS was 4.0 days (IQR: 3.0–7.0). Thirty-day readmission rates were 7% for Early Discharge, 8% for Standard Discharge, and 12% for Late Discharge. On multivariable regression analysis, risk factors significantly associated with a shorter LOS included independent functional status, minimally invasive approach, and absence of ostomy or additional bowel resection (all p < 0.001). Perioperative variables can be used to develop a model to identify patients eligible for early discharge after right colectomy for colon cancer. Efforts to decrease the overall median length of stay should focus on optimization of modifiable risk factors.

24 May 2024 in Annals of Surgery
Verified
Journal Article
Open access
LHLejla Hadzikadic-Gusic
Lejla Hadzikadic-Gusic
JBJessica Bilz
Jessica Bilz
DBDanielle Boselli
Danielle Boselli
JSJames Symanowski
James Symanowski
MWMichelle Wallander
Michelle Wallander
RWRichard L White
Richard L White
Objective: Compare radioactive seed localization (RSL) and wire-guided localization (WL) for nonpalpable malignant breast disease. Background: While WL has been the most common approach for localization of nonpalpable breast tumors, other techniques such as RSL, intraoperative ultrasound, radioactive intraoperative occult lesion localization, hematoma localization, radar localization, and magnetic seed localization have been suggested as safe and efficacious alternatives. However, very few randomized controlled trials have compared these localization techniques. Methods: Between July 2015 and January 2021, 400 women with nonpalpable malignant breast disease were randomized 1:1 to RSL or WL, stratified by the surgeon and invasive disease status. The primary outcome was initial resection negative margin rates. Secondary outcomes included time efficiencies, cost, and satisfaction. Results: There was no significant difference in negative margin rates between RSL and WL [RSL 0.80 (95% CI: 0.75–0.86) vs WL 0.85 (95% CI: 0.80–0.89); P =0.29]. RSL received better patient scores for anxiety [OR=2.62 (95% CI: 1.79–3.84); P <0.01], pain [OR=2.50 (95% CI: 1.69–3.71); P <0.01], and overall satisfaction [OR=3.24 (95% CI: 1.70–6.22); P <0.01] compared with WL. Radiologists and surgeons associated RSL with better convenience [OR=3.32 (95% CI: 1.65–6.69); P <0.01] and satisfaction of surgical procedure conduct [OR=1.67 (95% CI: 1.09–2.58); P =0.02]. Time in radiology did not differ [RSL mean (SD) 12.8±9.5 min vs. WL 11.4±6.0 min; P =0.18]. RSL incurred a $600 higher cost than WL. Conclusions: The results of the largest randomized controlled trial in the United States support RSL as an acceptable alternative to WL in the treatment of nonpalpable malignant breast disease. While RSL was not superior to WL in achievement of negative margins, patients and providers reported improved satisfaction scores.

15 July 2025 in Clinical Lymphoma Myeloma and Leukemia
Verified
Journal Article
Open access
CRCesar Rodriguez
Cesar Rodriguez
MTMelanie Tam
Melanie Tam
DHDavid Hurd
David Hurd
EDEmily V. Dressler
Emily V. Dressler
SKSarada Krishnamurthy
Sarada Krishnamurthy
KDKatie E. Duckworth
Katie E. Duckworth
Patients with newly diagnosed multiple myeloma undergo induction chemotherapy, followed by high-dose chemotherapy and autologous hematopoietic cell transplant (auto-HCT). The impact of auto-HCT on cognitive function is not well understood. We evaluated longitudinal changes in cognitive function after auto-HCT in patients with multiple myeloma. Patients with newly diagnosed multiple myeloma who completed induction chemotherapy and underwent pre-transplant evaluation were enrolled prospectively. Patients completed the self-administered gerocognitive exam (SAGE) and specialist-administered Montreal cognitive assessment (MoCA) at 3 time points: pre-transplant (baseline), 100-days post-transplant, and 1-year post-transplant. Scores were reported as means and standard deviations. Paired t-tests evaluated longitudinal differences. Thirty-eight (100%) participants completed the MoCA and SAGE at baseline and 100-days post-transplant, and nineteen (50%) participants completed both at 1-year post-transplant. The mean total MoCA score was 25.00 (SD = 3.05) at baseline, 25.87 (SD = 2.68) at 100-days post-transplant, and 26.00 (SD = 2.81) at 1-year post-transplant. The mean total SAGE score was 17.00 (SD = 3.89) at baseline, 17.76 (SD = 3.07) at 100-days post-transplant, and 18.18 (SD = 3.23) at 1-year post-transplant. At 100-days post-transplant, the mean change from baseline in MoCA score was 0.87 (SD = 3.16; P = .10) and the mean change in SAGE score was 0.76 (SD = 2.62; P = .08). Participants did not indicate a preference for self-administered versus provider-administered measures. Our study shows that auto-HCT was not associated with cognitive decline on objective assessment. Cognitive assessment is feasible and acceptable, with good correlation between self-administered tests and those administered by trained specialists.